Clinical Trials Directory

Trials / Completed

CompletedNCT03780712

Immune Dysfunction in Newborn Sepsis

Neonatal Immune Dysfunction Associated to the Risk of Newborn Sepsis in Benin

Status
Completed
Phase
Study type
Observational
Enrollment
585 (actual)
Sponsor
BioMérieux · Industry
Sex
All
Age
Healthy volunteers
Not accepted

Summary

The aim of the project is to study neonatal immune dysfunction associated to the risk of newborn sepsis in a malaria endemic area in Benin.

Detailed description

The fetal immunological responses maturate gradually during the last 3 months of pregnancy. To respond to pathogens, newborns depend essentially on their innate immune system. Premature babies have a significant impairment of innate and immune regulatory functions, thus promoting neonatal sepsis. In addition, chronic infections during pregnancy, including those of parasitic origin, fetal immunity. In utero exposure to P. falciparum antigens impacts particularly the newborn immune development and is a risk factor predisposing to malaria and also to other infections during the first year of life. The major objectives are to assess: * The relevance of a host biomarker driven diagnostic of sepsis in newborns, * The relevance of immune markers as indicators of sepsis incidence, secondary infections occurrence, and mortality * The role of novel diagnostic techniques (FilmArray panels) as part of the microbiological diagnostic, * The immunological profile of the infants in the 3 first months of life. The targeted population is newborns with a high risk to develop sepsis recruited at delivery compared to a control infant population with a low infection risk.

Conditions

Interventions

TypeNameDescription
OTHERNon applicableNo intervention as it is an observational study

Timeline

Start date
2016-04-17
Primary completion
2018-03-12
Completion
2018-03-12
First posted
2018-12-19
Last updated
2018-12-19

Source: ClinicalTrials.gov record NCT03780712. Inclusion in this directory is not an endorsement.